Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL

"Newly diagnosed Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (Ph-negative B-ALL) patients aged 18-60 years were enrolled.~Treatment Protocol~1. Low-intensity chemotherapy (VIP regimen)~ * V (Vincristine): 1.4 mg/m² (max 2 mg) on days 1 and 8.~ * I (Idarubicin): 8 mg/m²/day on days 1 and 8.~ * P (Prednisone): 60 mg/m²/day (max 100 mg/day) or equivalent dexamethasone dose on days 1-14.~2. Sequential induction therapy:~ * Blinatumomab administered for 2 weeks following the VIP regimen.~3. Consolidation therapy for morphological complete remission (CR)~ * Patients achieving CR receive two cycles of consolidation chemotherapy:~ * Cycle 1: VDCP regimen (Vincristine, Daunorubicin, Cyclophosphamide, Prednisone).~ * Cycle 2: VP + HD-MTX regimen (Vincristine, Prednisone + High-Dose Methotrexate).~4. Allogeneic hematopoietic stem cell transplantation (allo-HSCT):~ * Patients with multiparameter flow cytometry-confirmed minimal res"